A novel carbazole derivative, MHY407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage

European Journal of Pharmacology

Volumn 697, Issue 1-3, 2012, Pages 24-31

  Yoon, Sungpil ^a   Kim, Ju Hwa ^a   Lee, Young Ju ^b   Ahn, Mee Young ^b   Choi, Gayoung ^a   Kim, Won Ki ^a   Yang, Zunhua ^b   Lee, Hye Jin ^b   Moon, Hyung Ryong ^b   Kim, Hyung Sik ^b  

^a National Cancer Center   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

DNA damage; Doxorubicin; Etoposide; MHY407; p21; Radiation

Indexed keywords

9 METHYL 2 (OXIRAN 2 YLMETHOXY) 9H CARBAZOLE; CARBAZOLE DERIVATIVE; CELL DNA; CYCLIN D1; DOXORUBICIN; ETOPOSIDE; MHY 407; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBAZOLES; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOXORUBICIN; EPOXY COMPOUNDS; ETOPOSIDE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MCF-7 CELLS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; S PHASE CELL CYCLE CHECKPOINTS; TIME FACTORS;

EID: 84869502196     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.10.001     Document Type: Article

References (34)

1. A.M. Abukhdeir, and B.H. Park P21 and p27: roles in carcinogenesis and drug resistance Expert Rev. Mol. Med. 10 2008 e19
2. C. Asche, and M. Demeunynck Antitumor carbazoles Anticancer Agents Med. Chem. 7 2007 247 267
3. Bandgar, B.P., Adsul, L.K., Lonikar, S.V., Chavan, H.V., Shringare, S.N., Patil, S.A., Jalde, S.S., Koti, B.A., Dhole, N.A., Gacche, R.N., Shirfule, A., 2012. Synthesis of novel carbazole chalcones as radical scavenger, antimicrobial and cancer chemopreventive agents. J. Enzyme Inhib. Med. Chem. (Epub ahead of print).
4. G.L. Bidwell 3rd, and D. Raucher Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc Biochem. Pharmacol. 71 2006 248 256
5. L. Biganzoli, A. Minisini, M. Aapro, and A. Di Leo Chemotherapy for metastatic breast cancer Curr. Opin. Obstet. Gynecol. 16 2004 37 41
6. D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast cancer in the elderly J. Clin. Oncol. 25 2007 1882 1890
7. H.L. Devlin, P.C. Mack, R.A. Burich, P.H. Gumerlock, H.J. Kung, M. Mudryj, and R.W deVere White Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells Mol. Cancer Res. 6 2008 808 818
8. R.O. Dillman, N.M. Barth, L.A. VanderMolen, K. Allen, L.D. Beutel, and S. Chico High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants Am. J. Clin. Oncol. 28 2005 281 288
9. S. Gluck Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin Oncologist 10 2005 780 791
10. C.J. Hsiao, T.K. Li, Y.L. Chan, L.W. Hsin, C.H. Liao, C.H. Lee, P.C. Lyu, and J.H. Guh WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers Biochem. Pharmacol. 75 2008 847 856
11. M.J. Hsu, Y. Chao, Y.H. Chang, F.M. Ho, L.J. Huang, Y.L. Huang, T.Y. Luh, C.P. Chen, and W.W. Lin Cell apoptosis induced by a synthetic carbazole compound LCY-2-CHO is mediated through activation of caspase and mitochondrial pathways Biochem. Pharmacol. 70 2005 102 112
12. C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, C. Williams, and J.A. Green Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann. Oncol. 18 2007 409 420
13. P.D. Inskip, L.L. Robison, M. Stovall, S.A. Smith, S. Hammond, A.C. Mertens, J.A. Whitton, L. Diller, L. Kenney, S.S. Donaldson, A.T. Meadows, and J.P. Neglia Radiation dose and breast cancer risk in the childhood cancer survivor study J. Clin. Oncol. 27 2009 3901 3907
14. V.G. Kaklamani, and W.J. Gradishar Adjuvant therapy of breast cancer Cancer Invest. 23 2005 548 560
15. T. Kawabe G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther. 3 2004 513 519
16. J.H. Kim, M. Chae, W.K. Kim, Y.J. Kim, H.S. Kang, H.S. Kim, and S. Yoon Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein Br. J. Pharmacol. 162 2011 773 784
17. J.H. Kim, T.H. Kim, H.S. Kang, J. Ro, H.S. Kim, and S. Yoon SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin Biochem. Biophys. Res. Commun. 387 2009 450 455
18. J.H. Kim, S.C. Lee, J. Ro, H.S. Kang, H.S. Kim, and S. Yoon Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines Biochem. Pharmacol. 79 2010 373 380
19. W.K. Kim, J.H. Kim, K. Yoon, S. Kim, J. Ro, H.S. Kang, and S. Yoon Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest Invest. New Drugs 30 2011 1311 1318
20. Y.K. Kim, Y.J. Song, D.W. Seo, D.W. Kang, H.Y. Lee, D.K. Rhee, J.W. Han, C.M. Ahn, S. Lee, and S.N. Kim Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein Biochem. Biophys. Res. Commun. 355 2007 136 142
21. S.H. Kweon, J.H. Song, and T.S. Kim Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression Biochem. Biophys. Res. Commun. 395 2010 104 110
22. A.F. Leary, B. Sirohi, and S.R. Johnston Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer Breast Cancer Res. 9 2007 112
23. K.H. Lee, K.J. Moon, H.S. Kim, B.C. Yoo, S. Park, H. Lee, S. Kwon, E.S. Lee, and S. Yoon Increased cytoplasmic levels of CIS, SOCS1, SOCS2, or SOCS3 are required for nuclear translocation FEBS Lett. 582 2008 2319 2324
24. J.M. Llovet Updated treatment approach to hepatocellular carcinoma J. Gastroenterol. 40 2005 225 235
25. S. Maddika, S.R. Ande, S. Panigrahi, T. Paranjothy, K. Weglarczyk, A. Zuse, M. Eshraghi, K.D. Manda, E. Wiechec, and M. Los Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy Drug Resist. Update 10 2007 13 29
26. T. Nagappan, P. Ramasamy, M.E. Wahid, T.C. Segaran, and C.S. Vairappan Biological activity of carbazole alkaloids and essential oil of Murraya koenigii against antibiotic resistant microbes and cancer cell lines Molecules 16 2011 9651 9664
27. L. Nagarapu, H.K. Gaikwad, K. Sarikonda, J. Mateti, R. Bantu, P.S. Raghu, K.M. Manda, and S.V. Kalvendi Synthesis and cytotoxicity evaluation of 1-[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]-3-aryl-1H-pyrazole-5-carboxyli c acid derivatives Eur. J. Med. Chem. 45 2010 4720 4725
28. J.L. Nitiss DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage Curr. Opin. Invest. Drugs 3 2002 1512 1516
29. N. Patra, U. De, J.A. Kang, J.M. Kim, M.Y. Ahn, J. Lee, J.H. Jung, H.Y. Chung, H.R. Moon, and H.S. Kim A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells Eur. J. Pharmacol. 658 2011 98 107
30. C.J. Sherr, and F. McCormick The RB and p53 pathways in cancer Cancer Cell 2 2002 103 112
31. H.J. Shin, J.Y. Kim, L. Hampson, H. Pyo, H.J. Baek, S.A. Roberts, J.H. Hendry, and I.N. Hampson Human papillomavirus 16 E6 increases the radiosensitivity of p53-mutated cervical cancer cells, associated with up-regulation of aurora A Int. J. Radiat. Biol. 86 2010 769 779
32. S. Solier, O. Sordet, K.W. Kohn, and Y. Pommier Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways Mol. Cell Biol. 29 2009 68 82
33. H. Thomadaki, and A. Scorilas Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol Biol. Chem. 389 2008 1427 1434
34. F. Van Valen, S. Fulda, K.L. Schafer, B. Truckenbrod, M. Hotfilder, C. Poremba, K.M. Debatin, and W. Winkelmann Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells Int. J. Cancer 107 2003 929 940